Manufacturer
BAXTER ONCOLOGY GMBH
Contents
Azacitidine
Indication
Myelodysplastic disease.
Instruction
Via SC inj or IV infusion over 10-40 min for 7 days, followed by a rest period of 21 days (28-day cycle),
Drug interaction
No information provided